📊 PCYN Key Takeaways
Is Procyon Corp. (PCYN) a Good Investment?
Procyon Corp demonstrates a critical operational disconnect: excellent gross margins of 78.1% are negated by severe cost control failures, resulting in negative operating margins (-4.6%) and net losses despite 6.4% revenue growth. Deteriorating profitability (-9% net income YoY) and negative free cash flow (-125.2K) indicate unsustainable business dynamics. While the balance sheet is solid with minimal debt, the company must achieve dramatic operational efficiency improvements before cash reserves are depleted.
Why Buy Procyon Corp. Stock? PCYN Key Strengths
- Exceptional gross margin of 78.1% demonstrates strong underlying product economics and pricing power
- Solid balance sheet with minimal leverage (0.02x debt/equity ratio) provides financial stability
- Strong liquidity position with 3.08x current ratio and 326.1K cash reserves provide operational runway
PCYN Stock Risks: Procyon Corp. Investment Risks
- Persistent unprofitability at operating level (-231.7K operating income) despite substantial gross profits reveals severe cost discipline issues
- Negative free cash flow of -125.2K combined with deteriorating net income (-9% YoY) indicates unsustainable cash burn trajectory
- Operating expenses exceed 80% of gross profit, consuming all margin gains and requiring fundamental restructuring to achieve viability
- Data freshness concern with most recent period ending June 30, 2024; absence of recent filings limits current performance visibility
Key Metrics to Watch
- Operating margin trend toward breakeven or positive - critical for investment thesis viability
- Free cash flow inflection point - must achieve positive FCF within 2-3 reporting periods
- Operating expense ratio relative to gross profit - track progress toward 50% target for profitability
Procyon Corp. (PCYN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.08x current ratio provides a solid financial cushion.
PCYN Profit Margin, ROE & Profitability Analysis
PCYN vs Healthcare Sector: How Procyon Corp. Compares
How Procyon Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Procyon Corp. Stock Overvalued? PCYN Valuation Analysis 2026
Based on fundamental analysis, Procyon Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Procyon Corp. Balance Sheet: PCYN Debt, Cash & Liquidity
PCYN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Procyon Corp.'s revenue has grown significantly by 15% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
PCYN Revenue Growth, EPS Growth & YoY Performance
PCYN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $1.1M | -$8.2K | $0.00 |
| Q2 2024 | $1.2M | -$8.2K | $0.00 |
| Q1 2024 | $1.2M | -$8.2K | $0.00 |
| Q3 2023 | $1.1M | -$8.2K | $0.00 |
| Q1 2023 | $1.2M | -$8.2K | $0.00 |
| Q3 2022 | $1.0M | $21.7K | $0.00 |
| Q2 2022 | $1.2M | -$8.2K | $0.00 |
| Q1 2022 | $1.2M | $42.5K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Procyon Corp. Dividends, Buybacks & Capital Allocation
PCYN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Procyon Corp. (CIK: 0000812306)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PCYN
What is the AI rating for PCYN?
Procyon Corp. (PCYN) has an AI rating of SELL with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PCYN's key strengths?
Claude: Exceptional gross margin of 78.1% demonstrates strong underlying product economics and pricing power. Solid balance sheet with minimal leverage (0.02x debt/equity ratio) provides financial stability.
What are the risks of investing in PCYN?
Claude: Persistent unprofitability at operating level (-231.7K operating income) despite substantial gross profits reveals severe cost discipline issues. Negative free cash flow of -125.2K combined with deteriorating net income (-9% YoY) indicates unsustainable cash burn trajectory.
What is PCYN's revenue and growth?
Procyon Corp. reported revenue of $5.0M.
Does PCYN pay dividends?
Procyon Corp. does not currently pay dividends.
Where can I find PCYN SEC filings?
Official SEC filings for Procyon Corp. (CIK: 0000812306) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PCYN's EPS?
Procyon Corp. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is PCYN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Procyon Corp. has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is PCYN stock overvalued or undervalued?
Valuation metrics for PCYN: ROE of -14.9% (sector avg: 15%), net margin of -6.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy PCYN stock in 2026?
Our dual AI analysis gives Procyon Corp. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PCYN's free cash flow?
Procyon Corp.'s operating cash flow is $-61.3K, with capital expenditures of $63.9K. FCF margin is -2.5%.
How does PCYN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -6.8% (avg: 12%), ROE -14.9% (avg: 15%), current ratio 3.08 (avg: 2).